Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most safety-related statements about clonazepam sedation, impaired coordination, dependence/withdrawal, and need for gradual taper are supported by the provided KLONOPIN labeling excerpts. However, multiple manufacturer/brand-interchangeability and formulation/dissolution-related claims are not supported by the supplied prescribing information and include speculation beyond the label.
Category Scores
Accurate Statements
Clonazepam can cause sedation.
Section 6 (Adverse Reactions): most frequently occurring side effects referable to CNS depression including drowsiness/somnolence.
Clonazepam can cause impaired coordination.
Section 6 (Adverse Reactions): coordination abnormal is listed as a common adverse event (panic disorder study). Ataxia/coordination abnormal reported.
Clonazepam can cause dependence.
Section 5 (Warnings): dependence and withdrawal reactions discussed; use gradual taper to discontinue/reduce dosage to reduce withdrawal reactions.
Clonazepam can cause withdrawal if stopped abruptly.
Section 5 (Warnings): abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions, which may be life-threatening (e.g., seizures).
Benzodiazepines, including clonazepam, can cause dependence and withdrawal if stopped abruptly.
Section 5 (Warnings): withdrawal risk emphasized for benzodiazepines including Klonopin; abrupt discontinuation/rapid reduction can precipitate acute withdrawal reactions.
Unsupported Statements
Aurobindo and Advagen both make or market clonazepam.
No manufacturer/product-availability or marketing statements are present in the provided KLONOPIN label excerpts.
Aurobindo and Advagen are different manufacturers/brands of clonazepam.
No manufacturer/brand attribution for clonazepam products is provided in the supplied label excerpts.
If two products are both clonazepam (same strength and dosage form), they are intended to provide the same active ingredient and therapeutic effect.
The provided label does not address interchangeability or therapeutic equivalence across clonazepam manufacturers/brands.
When prescribed as clonazepam, clonazepam products with the same strength and dosage form are typically considered interchangeable.
The provided label does not mention interchangeability between clonazepam brands/products.
The active ingredient in Aurobindo and Advagen clonazepam is typically the same (clonazepam).
No information in the provided label excerpts supports claims about specific Aurobindo/Advagen products.
Differences between Aurobindo and Advagen clonazepam can include inactive ingredients (excipients).
The provided label excerpts do not discuss excipients for specific manufacturers/brands.
Differences between Aurobindo and Advagen clonazepam can include tablet appearance and packaging.
The provided label excerpts do not discuss appearance/packaging differences for other manufacturers.
Differences in excipients can matter for some patients who have trouble with a specific excipient.
The provided label excerpts do not address patient effects related to excipient differences.
Switching between brand-to-brand clonazepam products can sometimes lead to noticeable differences.
No switch/interchange/effect-on-symptoms statements are present in the provided label excerpts.
Brand-to-brand differences can be due to different tablet formulations/excipients.
Not supported by the provided label excerpts.
Brand-to-brand differences can be due to different dissolution/absorption behavior between products.
Not supported by the provided label excerpts (pharmacokinetics discussed for clonazepam generally within the label, not comparative brand differences).
Brand-to-brand differences can be due to different strength presentation or tablet size.
Not supported by the provided label excerpts.
Clonazepam tablets are generally not extended-release in common formulations.
The provided label excerpts do not discuss extended-release vs immediate-release product types.
After a switch, a patient may experience sedation, breakthrough symptoms, or withdrawal-like effects.
The provided label excerpts discuss CNS effects and withdrawal with abrupt discontinuation/rapid reduction, but do not address switching between manufacturers/brands.
Clinicians may re-check the dose and formulation and stabilize a patient on one consistent product if symptoms occur after a switch.
No label support for switching management between brands/products.
There is not enough public, consistent information in the prompt to rank one manufacturer above another.
This is a meta-commentary not addressed by the provided label; the label does not rank manufacturers.
Safety is primarily driven by clonazepam itself rather than whether it is from Aurobindo or Advagen.
The provided label excerpts do not address manufacturer-specific safety comparisons.
Contradictions
Important Omissions
No mention (in the audited AI claims) of the label’s specific discontinuation/taper schedule details (e.g., for panic disorder adults: decrease of 0.125 mg twice daily every 3 days until complete withdrawal).
Importance:
Moderate
No mention of key contraindications (e.g., history of sensitivity to benzodiazepines; significant liver disease; acute narrow angle glaucoma) relevant to safety screening.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Label-supported risks (sedation/CNS depression, coordination abnormality, dependence/withdrawal with abrupt cessation) are correctly described. However, multiple unsupported brand/interchangeability/switching claims could mislead about effects after switching or downplay the need for label-based tapering/clinical safeguards; this introduces moderate risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Manufacturer/brand interchangeability, excipient/formulation/dissolution-based switching speculation, and management after switching are not supported by the provided KLONOPIN label excerpts.
Suggested Improvement
Limit claims to label-supported information: CNS depression adverse effects (drowsiness/somnolence, ataxia/coordination abnormal), and dependence/withdrawal risk mitigated by gradual taper. Avoid making manufacturer-specific or interchangeability/switch-effect statements not present in the provided label text.